Comparative Pharmacology
Head-to-head clinical analysis: TURQOZ versus WILPO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TURQOZ versus WILPO.
TURQOZ vs WILPO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TURQOZ is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
Wilpo (setmelanotide) is a melanocortin 4 receptor (MC4R) agonist that activates the MC4R pathway to reduce appetite and increase energy expenditure.
400 mg orally once daily.
WILPO is not a known or approved drug. No standard dosing information available.
None Documented
None Documented
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment
Terminal elimination half-life of 12 hours (range 10-14 h). Steady-state achieved after 2-3 days. Requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (80% unchanged) with 10% fecal, 5% biliary, 5% other
Primarily renal (unchanged: 60%, glucuronide conjugate: 20%), biliary/fecal: 15%, other: 5%.
Category C
Category C
Unknown
Unknown